- Home
- PHI vs SRRK Comparison
PHI vs SRRK Comparison
Compare PHI & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PHI | SRRK |
|---|---|---|
| Founded | 1928 | 2012 |
| Country | Philippines | United States |
| Employees | N/A | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7B | 4.6B |
| IPO Year | 1953 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PHI | SRRK |
|---|---|---|
| Price | $21.44 | $41.82 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 9 |
| Target Price | N/A | ★ $47.88 |
| AVG Volume (30 Days) | 48.9K | ★ 1.1M |
| Earning Date | 11-11-2025 | 11-14-2025 |
| Dividend Yield | ★ 5.57% | N/A |
| EPS Growth | ★ 9.36 | N/A |
| EPS | ★ 2.32 | N/A |
| Revenue | ★ $3,761,997,877.00 | N/A |
| Revenue This Year | $2.70 | N/A |
| Revenue Next Year | $2.64 | $20,271.77 |
| P/E Ratio | $9.17 | ★ N/A |
| Revenue Growth | ★ 1.69 | N/A |
| 52 Week Low | $18.61 | $22.71 |
| 52 Week High | $25.12 | $48.28 |
Technical Indicators
Market Signals| Indicator | PHI | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 45.88 |
| Support Level | $21.50 | $41.20 |
| Resistance Level | $21.95 | $46.14 |
| Average True Range (ATR) | 0.34 | 1.70 |
| MACD | -0.05 | -0.73 |
| Stochastic Oscillator | 34.37 | 10.14 |
Price Performance
Historical ComparisonAbout PHI PLDT Inc. Sponsored ADR
PLDT Inc is the telecommunications carrier in the Philippines. The company's business activities include three business units: Wireless, Fixed Line and Others. The wireless segment consists of mobile telecommunications services provided by Smart and DMPI, and Fixed-line telecommunications services mainly provided by PLDT. It also provides fixed-line services through PLDT's subsidiaries.
About SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.